Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 11,201–11,300 of 15,747
Benkeser, D. C., Diaz, I. M., & Ran, J. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2103.02643 · Cited by 16
Nazar, F. A. (2021) · Thesis Commons (OSF Preprints) · doi:10.31237/osf.io/trz5s · Cited by 2
Long‐term effects of influenza and Bacille Calmette–Guérin vaccination on systemic inflammation
Debisarun, P. A., Röring, R. J., Bulut, O. P., ten Doesschate, T., van der Vaart, T. W., Kumar, V., Lemmers, H., Dijkstra, H., Janssen, A. B., Veerman, K. M., et al. (2025) · Clinical & Translational Immunology · doi:10.1002/cti2.70047 · Cited by 3
Unilateral Pleural Effusion after Third Dose of BNT162b2 mRNA Vaccination: Case Report
Athanasiou, N., Antonoglou, A., Ioannou, M., Jahaj, E., & Katsaounou, P. A. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030391 · Cited by 2
“5 million deaths worldwide and vaccination remains the best form of prevention currently available [1,2].”
BackgroundSayed, A. A. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1327944 · Cited by 4
“However, it is essential to note that the vaccines underwent rigorous clinical trials, adhering to established safety protocols (50).”
BackgroundScRNA-Seq reveals T cell immunity in COVID-19 patients and implications for immunotherapy
Yao, Z., Feng, Z., Zhang, H., & Zhang, B. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114663 · Cited by 3
Chiarenza, A., Aluisio, G. V., Parrinello, N. L., Marino, S., Corsale, A. M., Privitera, G. F., Azgomi, M. S., Spina, E. L., Cambria, D., Curtopelle, A., et al. (2025) · Biomarker Research · doi:10.1186/s40364-025-00734-w · Cited by 2
“In the Israelian series of 2030 CLL patients receiving 2 doses of the BNT162b2 vaccine, the protective effect of vaccination was 46% [24], which was lower than the 95% protection reported in the pivotal phase III BNT162b2 vaccine trial [25].”
Artificial Lungs for Lung Failure in the Era of COVID-19 Pandemic: Contemporary Review
Naito, N., & Shigemura, N. (2023) · Transplantation · doi:10.1097/tp.0000000000004606 · Cited by 2
A COVID-19 primer for primary care clinicians
Burkhardt, M. C., Winter, K., Alter, S. J., & Klatte, J. M. (2022) · Current problems in pediatric and adolescent health care · doi:10.1016/j.cppeds.2022.101180 · Cited by 2
“1%.(77) A more recent meta-analysis published in September 2021 estimated the pooled effectiveness of the Pfizer-BioNTech vaccine to be 92.”
BackgroundA comprehensive comparison between COVID-19 vaccines: a reviewPreprint
Ng, C. W., Liang, S., & Li, Y. (2021) · doi:10.14293/s2199-1006.1.sor-.ppuc2qo.v1 · Cited by 2
“A probability of higher than 83% (Polack et al., 2020) that at least one adverse event is 103 detected.”
BackgroundInfluentialAnticoagulation as a therapeutic strategy for hospitalised patients with COVID-19
Cullivan, S., Sholzberg, M., Áinle, F. N., & Kevane, B. (2022) · Thrombosis Update · doi:10.1016/j.tru.2022.100097 · Cited by 3
Could Drug Delivery Systems Be Enhancers for Therapy against KRAS-driven Cancers?
Khusnutdinov, R. (2024) · Reviews and Advances in Chemistry · doi:10.1134/s2634827624600312 · Cited by 2
(2023) · doi:10.1101/2023.10.04.560777 · Cited by 2
“Although vaccination with an ancestral SARS-CoV-2 whole spike vaccine provides protection against serious illness (1, 2), boosting immunity with ancestral vaccines is ineffective at preventing infection by Omicron variants (3-6).”
BackgroundKhan, M. S., Shakya, M., & Verma, C. K. (2024) · VirusDisease · doi:10.1007/s13337-024-00894-7 · Cited by 3
“A significant advancement in this effort has been the creation of mRNA [4, 36] and vector-based vaccines [29, 38, 46], such as those developed by Pfizer-BioNTech, Moderna, and Oxford-AstraZeneca.”
Vugts, A., & Havermans, R. C. (2022) · Wageningen Academic Publishers eBooks · doi:10.3920/978-90-8686-933-6_18 · Cited by 4
COVID-19 FAQs in Pediatric Cardiac Surgery: 2022 Perspective and Updates
Levy, E. R., Dearani, J. A., Blumenthal, J. A., Johnson, J. N., Overman, D. M., Stephens, E. H., & Chiotos, K. (2022) · World Journal for Pediatric and Congenital Heart Surgery · doi:10.1177/21501351221085966 · Cited by 2
Supraventricular tachycardia and deep vein thrombosis following Moderna vaccination: A case series
Bhandari, N., Chaudhary, A., Acharya, S., Acharya, S. S., Paudel, K., Karmacharya, R. M., Vaidya, S., Kunwar, K., & Bhatt, S. (2023) · Clinical Case Reports · doi:10.1002/ccr3.7065 · Cited by 1
Evaluating Vaccine Efficacy Against SARS-CoV-2 Infection
(2021) · doi:10.1101/2021.04.16.21255614 · Cited by 2
Kos, I. A., Kiefer, M., Brill, K., Cetin, O., Bittenbring, J. T., Ahlgrimm, M., Smola, S., Lohse, S., Christofyllakis, K., Kaddu‐Mulindwa, D., et al. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2116009 · Cited by 1
“Another prospective cohort study showed that patients with hematologic malignancies, who are treated with Bruton Tyrosine Kinase inhibitors (BTKIs), the JAK inhibitor ruxolitinib, the BCL-2 inhibitor venetoclax, or anti-CD20 antibodies, did not show any sufficient humoral immune response after two doses of BNT162b2 [8…”
BackgroundInfluentialLu, M., Liu, K., Peng, Y., Ding, Z., Li, Y., Tendu, A. A., Hu, X., Gao, G., Guo, W., Liu, H., et al. (2022) · Virologica Sinica · doi:10.1016/j.virs.2022.05.006 · Cited by 2
Current Directions in Research and Treatment of COVID-19
Wróblewski, K. (2021) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2020.00041 · Cited by 2
Advancing Protein‐Coding RNA Engineering: From Structural Refinement to Biomedical Implementation
Lu, X., Li, S., Chi, Y., Lin, S., Yuan, H., Lin, Z., Xiao, Y., Yin, H., Zuo, X., Cheng, R., et al. (2025) · Biotechnology Journal · doi:10.1002/biot.70038 · Cited by 2
App Raises Public Awareness of the Importance of COVID-19 VaccinationPreprint
Chew, P. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3798475 · Cited by 2
Soltanzadi, A., Mirmosayyeb, O., Moghaddam, A. M., Ghoshouni, H., & Ghajarzadeh, M. (2024) · Neurología · doi:10.1016/j.nrl.2022.10.002 · Cited by 2
Comparison of Antibody Responses After CoronaVac and BNT162b2 Vaccines in Healthcare Workers
GÜLTEKİN, E. O., & GÜLTEKİN, O. (2023) · Indian Journal of Microbiology · doi:10.1007/s12088-023-01098-1 · Cited by 2
Al‐Madhagi, H., Kanawati, A., & Tahan, Z. S. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18452 · Cited by 2
Ferreiro‐Iglesias, R., Piqueras, M., Ricart, E., Sempere, L., Roca, M., de Carpi, J. M., Benítez, O., Zabana, Y., Mañosa, M., Rodríguez‐Moranta, F., et al. (2022) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2022.03.004 · Cited by 2
Monitoring clinical trials in infectious diseases
DeMets, D. L., Fleming, T. R., & Ellenberg, S. S. (2021) · doi:10.46439/allergy.2.019 · Cited by 2
Turan, S. A., & Aydın, Ş. (2024) · Acta Neurologica Belgica · doi:10.1007/s13760-024-02536-7 · Cited by 2
“The BNT162b2 mRNA vaccine (Pfizer BioNTech; Comirnaty) has been shown to be efficacious in preventing the spread of the infection and preserving lives [2].”
A Review on Variant of Concern (Delta Variant of COVID 19)
Jangam, K. K., Vikhe, D. N., Jadhav, R. S., & Shinde, G. S. (2022) · Asian Journal of Research in Pharmaceutical Sciences · doi:10.52711/2231-5659.2022.00025 · Cited by 2
Hill, E., & Keeling, M. (2021) · Journal of the Royal Society Interface · doi:10.1101/2021.03.15.21253542 · Cited by 23
Alby‐Laurent, F., Ouedrani, A., Jatteau, P., Strullu, M., Walter‐Petrich, A., Mrad, C., Guilmatre, A., Ferreboeuf, M., Ray‐Lunven, A., Kaguelidou, F., et al. (2026) · Vaccine · doi:10.1016/j.vaccine.2025.128130 · Cited by 2
Vaccination against COVID-19 for hematologic patients: A review of clinical guidelines
Gavrilina, O. A., & Vasileva, A. N. (2021) · Гематология и трансфузиология · doi:10.35754/0234-5730-2021-66-3-458-470 · Cited by 3
Kasuga, I., Takeda, Y., SATO, T. A., & Mori, M. (2022) · Health Evaluation and Promotion · doi:10.7143/jhep.2021-32 · Cited by 2
Yang, K., Xu, K., Zhang, L., Han, Y., Zhou, D., Xia, Q., Dai, L., & Gao, G. (2023) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-1054 · Cited by 4
Mandatory COVID-19 vaccination for oral health professionals (OHPs) - Ethical appraisal
Mtolo, T. M., Motloba, P. D., & Wood, N. H. (2021) · South African Dental Journal · doi:10.17159/2519-0105/2021/v76no1a7 · Cited by 3
Laham, G., Martínez, A. P., Gimenez, W. R., et al. (2022) · medRxiv · doi:10.1101/2022.05.13.22275049 · Cited by 2
Forte, S., Toepp, A. J., Bray, R. A., Baran David, A., Gilgannon, L. T., Williams, T., Chen, S., Hooman, S., Gebel Howard, M., Herre John, M., et al. (2022) · Archives of Organ Transplantation · doi:10.17352/2640-7973.000019 · Cited by 2
Brave new RNA world(s): from prebiotic chemistry to gene regulation and RNA technology
Flores-García, A. A., Hernandez-Rodriguez, A., López-Brito, E. I., Nava-Domínguez, D. F., Pasapera, S. P., Pazos-Murillo, R. F., Pineda-Diaz, T., & Vázquez-Salazar, A. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2026.1813517 · Cited by 2
“Phase 3 trials then provided the clinical proof that these coupled design choices translated into strong protection against COVID-19 (Polack et al., 2020; Baden et al., 2021).”
Kurashima, K., Numano, T., Yoshino, A., Osawa, A., Takaku, Y., Kagiyama, N., & Yanagisawa, T. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.08.035 · Cited by 2
“In Japan, vaccination against COVID-19 began in March 2021, using the BNT162b2 (Pfizer-BioNTech) messenger RNA (mRNA) vaccine [3,4].”
Robles-Fontán, M. M., & Irizarry, R. A. (2021) · medRxiv · doi:10.1101/2021.12.19.21268070 · Cited by 2
Bird, S. M. (2022) · Pharmaceutical Statistics · doi:10.1002/pst.2217 · Cited by 1
Mandatory Vaccination Against COVID-19: Twitter Poll Analysis on Public Health Opinion
Ritschl, V., Eibensteiner, F., Mosor, E., Omara, M., Sperl, L., Nawaz, F. A., Sai, C. S., Cenanovic, M., Devkota, H. P., Hriberšek, M., et al. (2022) · JMIR Formative Research · doi:10.2196/35754 · Cited by 4
COVID-19 vaccine and immune response
Hıntıstan, S., & DEMİRAĞ, H. (2021) · Exploration of Immunology · doi:10.37349/ei.2021.00023 · Cited by 3
“The disadvantage is that the vaccine can be stored for 6 months at -70°C and 5 days in the refrigerator at 4°C [52-54].”
BackgroundMontero-Navarro, S., Sánchez-Más, J., Salar-Andreu, C., Payá, F. J. M., Orts-Ruiz, C., Botella-Rico, J. M., Tuells, J., & Rodríguez-Blanco, N. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.877232 · Cited by 3
“The type of adverse effect observed among physical therapists was similar to that of other health professionals (41, 45, 47), although the frequency of appearance showed variations in some studies, especially if we compared them with the non-health professional population (48).”
ResultMerits and Demerits of COVID-19 Vaccines
El-Nimr, N. (2021) · Journal of High Institute of Public Health · doi:10.21608/jhiph.2021.150582 · Cited by 3
Català, M., Burn, E., Rathod‐Mistry, T., et al. (2022) · medRxiv · doi:10.1101/2022.11.09.22282065 · Cited by 2
“086 GP visits (median [IQR]) 180 days 9 [4-17] 22 [12-36] 0.”
Kozawa, K., Miura, H., Kawamura, Y., Higashimoto, Y., Ihira, M., & Yoshikawa, T. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27895 · Cited by 2
“(mRNA) vaccines are highly effective in preventing severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and disease onset.(1) The mRNA contained in vaccines can activate innate immune”
BackgroundAnalysing deaths and confirmed cases of COVID-19 pandemic by analytical approaches
Chen, R.-M. (2022) · The European Physical Journal Special Topics · doi:10.1140/epjs/s11734-022-00535-4 · Cited by 2
“Nowadays more and more papers are focusing on the efficacy and effectiveness of vaccine against all sorts of variants of SARSCoV-2 [11,12].”
BackgroundTranslatability scoring in prospective and retrospective COVID drug development cases
Wendler, A., & Wehling, M. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03517-0 · Cited by 2
Paoletti, G., Pepys, J., Bragato, M. C., Paoletti, S., Piona, A., Messina, M., Racca, F., Ferri, S., Nappi, E., Costanzo, G., et al. (2023) · Vaccines · doi:10.3390/vaccines11050903 · Cited by 2
“Rarely have hypersensitivity reactions to BNT162b2, including delayed reactions suggesting cellular hypersensitivity, been reported [5]; the vaccine component that has been hypothesized to be involved as the potential eliciting allergen in patients with BNT162b2-induced hypersensitivity reactions is the excipient poly…”
BackgroundInfluentialCOVID-19 vaccination: the reality after clinical trials
Ruiz‐Galiana, J., Cantón, R., Ramos, P. D. L., Botella, A. G., García‐Lledó, A., Gómez‐Pavón, J., del Castillo, J. M. G., Hernández‐Sampelayo, T., Delgado, M. C. M., Martín‐Sánchez, F. J., et al. (2021) · Revista Española de Quimioterapia · doi:10.37201/req/035.2021 · Cited by 6
Mair, M. J., Maj‐Hes, A., Nussbaumer-Pröll, A. K., Puhr, R., Christenheit, A., Troch, M., Puhr, H. C., Starzer, A. M., Steindl, A., Eberl, S., et al. (2023) · Infectious Agents and Cancer · doi:10.1186/s13027-023-00487-x · Cited by 2
Educational Interventions to Promote COVID-19 Vaccination Among Parents
Pascucci, J. (2021) · Delaware Journal of Public Health · doi:10.32481/djph.2021.07.016 · Cited by 2
Preparing European Nephrology for the next pandemic: lessons from the ERACODA collaboration
Vart, P., Duivenvoorden, R., Franssen, C. F. M., et al. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac306 · Cited by 2
Coronavirus Disease-2019 Pneumonia
Sharifi, H., & Hsu, J. L. (2022) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2022.11.006 · Cited by 3
Butler, M., Tamborska, A., Wood, G. K., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3823441 · Cited by 2
(2022) · doi:10.1101/2022.05.13.22274960 · Cited by 2
“5 Although high vaccine efficacy was reported in phase 3 trials of mRNA-1273 and BNT162b2 in the general population, these trials excluded immunocompromised individuals, including those with underlying immunocompromising conditions and those prescribed immune-modifying therapies (with the exception of individuals with…”
BackgroundXu, S., Hong, V. X., Sy, L. S., Bruxvoort, K. J., Lewin, B. J., Han, B., Holmquist, K. J., & Qian, L. (2023) · JMIR Public Health and Surveillance · doi:10.2196/46318 · Cited by 3
Inoue, Y., Li, Y., Yamamoto, S., Fukunaga, A., Ishiwari, H., Ishii, M., Miyo, K., Ujiie, M., Sugiura, W., Ohmagari, N., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.10.037 · Cited by 2
YAMASAKI, E., Shimamoto, F., Nishikawa, H., Goto, M., Iwamoto, M., Kimura, K., Ukimura, A., OOSAKA, N., Taniguchi, K., Ono, F., et al. (2022) · In Vivo · doi:10.21873/invivo.13015 · Cited by 3
Inflammation durably imprints memory CD4+ T cellsPreprint
Gray-Gaillard, S. L., Solis, S. M., Chen, H. M., Monteiro, C., Ciabattoni, G. O., Samanovic, M. I., Cornelius, A. R., Williams, T., Geesey, E., Rodriguez, M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.15.516351 · Cited by 2
“In contrast, serum levels of inflammatory cytokines were low following vaccination 27 and only mild reactogenicity was reported 28–30 .”
InfluentialOtovestibular Symptoms of COVID-19 and Its Vaccines/Treatments
Cherchi, M. (2022) · Encyclopedia · doi:10.3390/encyclopedia2030080 · Cited by 3
“The original trial [92] included 43,548 participants (of whom 21,720 received the intervention and 21,828 received a placebo).”
BackgroundGülümsek, E., Öztürk, D. D., Öztürk, H. A., et al. (2023) · Case Reports in Infectious Diseases · doi:10.1155/2023/5122228 · Cited by 2
Cioffi, A. (2021) · Cadernos de Saúde Pública · doi:10.1590/0102-311x00003621 · Cited by 2
Humeral and cellular immune responses to SARS-CoV-2 vaccination in patients on peritoneal dialysis
Yu, Z.-Y., Lai, C., Lai, T., et al. (2023) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2023.02.011 · Cited by 2
Siddika, A., Rousseau, J., Veillette, F., Bouchard, C., Lu, Y., & Tremblay, J. P. (2026) · Cells · doi:10.3390/cells15100852 · Cited by 2
Jeong, W. J., So, B. H., Kim, H. M., Cha, K., Lee, W. J., Jeong, S., Choi, S. P., & Woo, S. H. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.08.013 · Cited by 3
Effect of COVID-19 Vaccines on Menstrual Cycle Changes and Quality of Life
Bilgin, Z., & Burcu, Ç. K. (2022) · Reproductive Medicine International · doi:10.23937/2643-4555/1710020 · Cited by 3
Visser, C., Yousefi, A., Nierman, M. C., Huisman, M. V., Gulpen, A. J. W., van Ommen, C. H., & Kruip, M. J. H. A. (2023) · Thrombosis Research · doi:10.1016/j.thromres.2023.06.005 · Cited by 2
Turabián, J. L. (2022) · Epidemiology International Journal · doi:10.23880/eij-16000219 · Cited by 2
Peebles, K., Arciuolo, R. J., Romano, A., Sell, J. L., Greene, S. K., Lim, S., Mulready-Ward, C., Ternier, A., Badenhop, B. P., Blaney, K., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac448 · Cited by 3
“While our primary analysis is comparable to the primary analysis of the Pfizer-BioNTech clinical trial [14], this secondary analysis reduces potential selection bias that could occur in the primary analysis, which restricts the analytic population to persons who remained uncensored until at least the start date of the…”
ResultOgando‐Rivas, E., Castillo, P., Yang, C., Trivedi, V., Zhang, D., Pohl‐Guimarães, F., Liu, R., Barpujari, A., Candelario, K. M., Méndez-Gómez, H., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101192 · Cited by 2
Burghardt, T., Thalmayr, S., Obeser, L., Pöhmerer, J., Yazdi, M., Höhn, M., Völkl, M., Sieber‐Schäfer, F., Zahler, S., Merkel, O. M., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.5c19141 · Cited by 2
Colaneri, M., Benedetto, A. D., Marvulli, L. N., Bocchio, F., Cutti, S., Marena, C., Calvi, M., & Bruno, R. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1920273 · Cited by 2
“On a brighter side, data from C4591001 Study have suggested a favorable safety profile for the BNT162b2, with mild-tomoderate and self-limited local reactions and systemic events.(1) Along with the beginning of vaccination programmes, ad hoc national pharmacovigilance systems have been implemented worldwide.”
Empty lipid nanoparticles (eLNPs) with adjuvant activity induce potent immune responses
Qiu, D., Yan, S., Chen, R., Wu, S., Nie, M., Yang, M., Liu, Y., Wu, Y. Y.-C., Xiong, H., Yuan, Q., et al. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70340 · Cited by 3
“broadly categorized into several types, including live attenuated vaccines, inactivated vaccines, subunit vaccine, virus vector-based vaccine and nucleic acid vaccines (Kemp et al., 2021; Polack et al., 2020).”
SARS-CoV-2 infection rates after different vaccination schemes: An online survey in Turkey
Baydar, O., Özen, Ş., Öztürk, B., Öztürk, B., Öztürk, E., Kitapci, M. T., & Kokturk, N. (2022) · Asian Pacific Journal of Tropical Medicine · doi:10.4103/1995-7645.340576 · Cited by 2
Li, J., Liang, S., Li, Y., Wu, J., Li, C., Gan, J., Li, W., & Wang, C. (2026) · Respiratory Research · doi:10.1186/s12931-025-03465-6 · Cited by 6
Kobayashi, H., Ouchi, T., Kitamura, W., et al. (2023) · Journal of the Japan Society of the Reticuloendothelial System · doi:10.3960/jslrt.23040 · Cited by 2
“Flow cytometric evaluation of the bone marrow reveals that a B-cell population did not harbor immunoglobulin light-chain restriction ( G ). the spike glycoprotein, 4,5 the antibodies generated by the vaccine can bind to erythrocytes via cross-reactivity.”
BackgroundIWAMOTO, Y., Kusunoki, H., Kamijima, Y., Sakai, R., Watanabe, Y., & Kakeya, H. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1795437 · Cited by 4
Connors, J. M. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab585 · Cited by 2
What 21st century medicine should be—history, vision, implementation, and opportunities
Hood, L., Price, N. D., & Evans, S. J. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.003.0003 · Cited by 2
Pettit, N., Zaidi, A., O’Neill, B., et al. (2021) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2021.06.004 · Cited by 2
Thammathiwat, T., Banjongjit, A., Chumnumsiriwath, P., Chompuk, L., Sripariwuth, A., Pongcharoen, S., & Kanjanabuch, T. (2022) · Vaccines · doi:10.3390/vaccines10111888 · Cited by 2
“The com on adverse vents of BNT162b2 injection incl e c e, muscle pain, and fever [10].”
BackgroundERS International Congress 2021: highlights from the Respiratory Infections Assembly
Meldrum, O. W., Belchamber, K. B. R., Chichirelo-Konstantynovych, K. D., Horton, K. L., Konstantynovych, T. V., Long, M. B., McDonnell, M. J., Perea, L., García‐Basteiro, A. L., Loebinger, M. R., et al. (2022) · ERJ Open Research · doi:10.1183/23120541.00642-2021 · Cited by 2
“mRNA vaccines had shown higher efficacy levels (51) by significantly reducing hospitalisation in fully-vaccinated individuals (52).”
BackgroundKang, H., Sun, Y., Fang, Z., Ding, W., Bai, T., Yang, K., & Jiang, D. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145010 · Cited by 2
Programmed cell death markers in COVID-19 survivors with and without sepsis
Mallarpu, C. S., Chelluri, S. I., Katragadda, T. K., Singarapu, M., Chelluri, L. K., & Madiraju, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1535938 · Cited by 3
Puga, M. A. M., de Oliveira, R. D., da Silva, P. V., Charu, V., Hedlin, H., Lu, D., Zhang, C. A., Shaw, B. J., Rosser, J. I., Seidman, J. C., et al. (2025) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2025.101031 · Cited by 5
COVID-19 Vaccination in Patients with Chronic Lymphocytic Leukaemia: What Can We Expect?
Din, M. A. U., & Jamshed, S. (2021) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2021.17.1.7 · Cited by 2
Skrami, E., Faragalli, A., Iommi, M., Morbidoni, M., Mancini, C., Guidi, A., Cardone, A., Pompili, M., Serafini, P., Appignanesi, R., et al. (2025) · Scientific Reports · doi:10.1038/s41598-024-84100-0 · Cited by 3
Huang, W., Chai, G. T., Thong, B. Y., et al. (2021) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001452 · Cited by 2
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.